A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Trial Profile

A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs AL 335/odalasvir/simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Nov 2017 This study has been completed in Germany as per European Clinical Trials Database.
    • 06 Nov 2017 Planned number of patients changed from 250 to 54.
    • 06 Nov 2017 Planned primary completion date changed from 6 Dec 2021 to 30 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top